Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Omega Therapeutics Inc (OMGA)

Omega Therapeutics Inc (OMGA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,409
  • Shares Outstanding, K 48,049
  • Annual Sales, $ 140 K
  • Annual Income, $ -68,280 K
  • 60-Month Beta -0.03
  • Price/Sales 2,235.61
  • Price/Cash Flow N/A
  • Price/Book 2.40
Trade OMGA with:

Options Overview Details

View History
  • Implied Volatility 117.11% ( -43.71%)
  • Historical Volatility 75.95%
  • IV Percentile 38%
  • IV Rank 36.12%
  • IV High 287.80% on 07/15/22
  • IV Low 20.60% on 06/24/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 955
  • Open Int (30-Day) 1,046

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.63
  • Number of Estimates 3
  • High Estimate -0.59
  • Low Estimate -0.69
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -43.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.49 +51.39%
on 11/04/22
7.49 -9.35%
on 11/21/22
+1.82 (+36.62%)
since 10/28/22
3-Month
3.88 +75.00%
on 10/11/22
9.00 -24.56%
on 09/14/22
+2.54 (+59.76%)
since 08/30/22
52-Week
1.98 +243.80%
on 06/01/22
18.61 -63.52%
on 12/02/21
-10.12 (-59.85%)
since 11/26/21

Most Recent Stories

More News
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 135.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

OMGA : 6.79 (+1.19%)
Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade

The consensus price target hints at a 229.3% upside potential for Omega Therapeutics, Inc. (OMGA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

OMGA : 6.79 (+1.19%)
Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

/PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 31.18 (+3.31%)
EVLO : 1.9900 (+2.58%)
FHTX : 6.66 (-1.04%)
MRNA : 171.70 (-0.84%)
OMGA : 6.79 (+1.19%)
RUBY : 0.2086 (-0.67%)
SANA : 4.75 (+0.85%)
MCRB : 6.96 (+4.66%)
Omega Therapeutics to Participate in Two Upcoming Investor Conferences

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)
Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...

OMGA : 6.79 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 7.48
2nd Resistance Point 7.21
1st Resistance Point 6.96
Last Price 6.79
1st Support Level 6.44
2nd Support Level 6.17
3rd Support Level 5.92

See More

52-Week High 18.61
Fibonacci 61.8% 12.26
Fibonacci 50% 10.29
Fibonacci 38.2% 8.33
Last Price 6.79
52-Week Low 1.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar